Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$9.47 USD
-0.08 (-0.84%)
Updated May 3, 2024 04:00 PM ET
After-Market: $9.47 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.50 | $15.00 | $5.00 | 9.95% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Centessa Pharmaceuticals PLC Sponsored ADR comes to $10.50. The forecasts range from a low of $5.00 to a high of $15.00. The average price target represents an increase of 9.95% from the last closing price of $9.55.
Analyst Price Targets (6 )
Broker Rating
Centessa Pharmaceuticals PLC Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy, representing 71.43% of all recommendations. A month ago, Strong Buy represented 71.43%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/1/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
3/15/2024 | Evercore Partners | Umer Raffat | Strong Buy | Strong Buy |
3/5/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
8/15/2023 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.57 |
ABR (Last week) | 1.57 |
# of Recs in ABR | 7 |
Average Target Price | $10.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | -0.41 |